Motor Cortex Reward Signaling in Parkinson Disease

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00558766
First received: November 14, 2007
Last updated: June 14, 2011
Last verified: June 2011
  Purpose

Background:

The brain releases signals to mark rewards for certain behavior. Some medications for Parkinson disease (PD) can cause some patients to engage in compulsive behavior, possibly because the medications affect this reward system.

By using transcranial magnetic stimulation (TMS), researchers can study brain activity when an individual receives a reward.

Objectives:

To learn how the brains of people with PD behave when rewarded.

To learn whether two common Parkinson medications (levodopa and pramipexole) change this behavior.

To compare reward signals in the brains of healthy volunteers with reward signals in the brains of people with PD.

Eligibility:

Women between 50 and 80 years of age and men between 45 and 80 years of age.

Participants will be divided into healthy volunteers and volunteers who have mild to moderate PD.

Design:

Prescreening will consist of a neurological examination and a series of questions about gambling habits and drug and alcohol use.

Participation in a TMS study involving a computer game simulation of a slot machine:

  • Before the simulation, participants will receive TMS to establish a baseline response rate.
  • During the simulation, participants will play a game in which they will receive real money.

TMS will be administered to each patient under three different conditions:

  • TMS administered when patients have not taken any Parkinson medication.
  • TMS administered after patients have taken levodopa.
  • TMS administered after patients have taken pramipexole....

Condition
Parkinson Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Motor Cortex Reward Signaling in Parkinson Disease

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Enrollment: 35
Study Start Date: November 2007
Estimated Study Completion Date: June 2011
Detailed Description:

The role of mesencephalic dopamine neurons in reward processing has been established in primates using electrophysiological techniques and in humans using functional neuroimaging. Their role is thought to be dual: i) they show sustained activity with the expectation of a future reward and ii) a phasic response after reward. Animal data indicate that these neurons, located in the midbrain areas A8-10, behave as a single functional unit when activated. They have rich projections to both the prefrontal and motor cortices where they synapse on interneurons and cortical pyramidal cells, producing primarily inhibition. Though their function is not fully understood, these projections clearly play an important role in motivation and learning. We have recently developed a pair of paradigms to detect a reward related signal in the primary motor cortex, where transcranial magnetic stimulation can be used to measure brief events. So far, we have tested healthy volunteers; we now intend to study Parkinson disease (PD) patients in order to help clarify the role of dopamine in effect of reward. The Parkinson patients will be tested both on and off levodopa/carbidopa and dopamine agonist medications. Our hypothesis is that the dopamine reward related signal will alter level of evocable inhibition in primary motor cortex. Using a behavioral paradigm that deliver intermittent reward, we aim to demonstrate, in treated and untreated PD patients a difference in the amount of cortical inhibition, i) when reward is expected compared to when reward is not expected and ii) after rewarded compared to unrewarded trials. We also aim to demonstrate a difference between their response and that of healthy controls.

  Eligibility

Ages Eligible for Study:   45 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

HEALTHY SUBJECTS:

-Age 45-70 years

PATIENTS:

  • Mild-moderate disease (Hoehn and Yahr stage 1-2).
  • Age 45-70 yrs

EXCLUSION CRITERIA:

  • Pre-menopausal status in women: Preliminary data in healthy, cycling women suggests that the variation in paired-pulse inhibition caused by the menstrual cycle may obscure the change in the response induced by the behavioral task.
  • Significant neurological or psychiatric history other than PD
  • Exposure to DA agonists within a month of study
  • History of habitual gambling, defined as either visiting casinos more than once per month or playing cards for money more than once per week or gambling over the internet more than once per month
  • Habitual consumption of more than two drinks a day, marijuana more than once a week or any other illicit drug use within the last three months
  • Significant abnormality on neurological examination other than PD related signs
  • Metal in the cranial cavity or eye, pacemaker, implanted pumps or stimulators
  • Use of non-PD related medications affecting the DA system, such as phenothiazine antihistamines (promethazine), antiemetics or decongestants in the last month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00558766

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00558766     History of Changes
Other Study ID Numbers: 080023, 08-N-0023
Study First Received: November 14, 2007
Last Updated: June 14, 2011
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Disruptive Behavior Disorders
Behavior
Gambling
Dopaminergic Mechanisms
Dopamine
Parkinson Disease
PD

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on July 24, 2014